Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000, and the company was listed on the GEM of the Shenzhen Stock Exchange on August 19, 2011 (stock code 300255). At present, the registered capital is 935 million yuan, the total assets are 3.5 billion yuan, and it has four production bases, nine subsidiaries, two overseas companies, and two joint venture companies. The company is a biochemical pharmaceutical enterprise integrating R & D, production, sales and import and export trade. In the field of heparin, it is a key high-tech enterprise with crude heparin products to low molecular weight heparin injection products and a complete heparin industry chain. It is a domestic heparin series. Leading enterprise in medicine.
Since its establishment, the company has mainly developed, produced and sold drugs for the treatment of cardiovascular and cerebrovascular diseases, diabetes drugs and anti-cancer drugs, and has actively expanded medical equipment, beauty, precision medicine and other fields. The products are exported to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, Philippines and other countries in the world.
The company pays attention to the development of new drugs and establishes the Changshan Pharmaceutical Research Institute, which aims to build the company's new drug R & D and information sharing center. Through the collection and analysis of the latest frontier information of new drugs, the selection of key R & D varieties, the integration of various R & D resources and R & D The introduction and training of talents and other ways to play the role of the company's innovation main body, serving the company's strategic goal of vigorously developing innovative drugs in the medium and long term, is an important measure for the company's strategic landing and has a positive significance for the company's future development. The company invests a lot of money every year in technological innovation, and has achieved a major breakthrough in innovation and cooperation.
In the next 1 to 3 years, the low-molecular-weight heparin aqueous injection preparation will enter the European and American markets. R & D and production enterprises. To achieve these goals, we will continue to strengthen R & D investment on the basis of existing product lines and increase innovative product projects with independent intellectual property rights.
CN
